![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Tempest Therpeutics Inc | NASDAQ:TPST | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.0344 | 1.97% | 1.7794 | 1.76 | 1.80 | 1.81 | 1.70 | 1.73 | 317,960 | 23:00:01 |
“In the second quarter, we presented promising trial results from TPST-1120, our novel PPARα antagonist, at the ASCO Annual Meeting. This was the first presentation of clinical data from a Tempest program: a significant milestone for the company that was enhanced by its selection for a podium presentation,” said Stephen R. Brady, chief executive officer of Tempest. “In addition to progress on our other programs, we closed a financing with support from both a new, top-tier investor and our founding investor that extended Tempest’s runway into the first quarter of 2024, providing additional stability during this turbulent time in the biotech capital markets.”
Recent Highlights
Planned Near-Term Milestones
Financial Results
Second Quarter
Year-to-Date
About Tempest Therapeutics
Tempest Therapeutics is a clinical-stage oncology company advancing small molecules that combine both tumor-targeted and immune-mediated mechanisms with the potential to treat a wide range of tumors. The company’s two novel clinical programs are TPST-1120 and TPST-1495, antagonists of PPARα and EP2/EP4, respectively. Both programs are advancing through clinical trials designed to study both agents as monotherapies and in combination with other approved agents. Tempest is also developing an orally-available inhibitor of TREX-1, a DNA repair enzyme that controls activation of the cGAS/STING pathway, an innate immune response pathway important for the development of anti-tumor immunity. Tempest is headquartered in South San Francisco. More information about Tempest can be found on the company’s website at www.tempesttx.com.
Forward-Looking Statements
This press release contains forward-looking statements (including within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended (the “Securities Act”)) concerning Tempest Therapeutics, Inc. (“Tempest Therapeutics”). These statements may discuss goals, intentions, and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the management of Tempest Therapeutics, as well as assumptions made by, and information currently available to, management of Tempest Therapeutics. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “could”, “expect,” “anticipate,” “plan,” “likely,” “believe,” “estimate,” “project,” “intend,” and other similar expressions. All statements that are not historical facts are forward-looking statements, including any statements regarding the timing and selection of development candidates, dose selection or commencement of, or availability of data from, clinical trials, the company’s guidance regarding cash resources, as well as our operational plans and the timing and ability to deliver on value-creating milestones. Forward-looking statements are based on information available to Tempest Therapeutics as of the date hereof and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement. These and other risks are described in greater detail in the Form 10-Q filed by Tempest Therapeutics with the Securities and Exchange Commission on August 15, 2022. Except as required by applicable law, Tempest Therapeutics undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise. These forward-looking statements should not be relied upon as representing Tempest Therapeutics’ views as of any date subsequent to the date of this press release and should not be relied upon as prediction of future events. In light of the foregoing, investors are urged not to rely on any forward-looking statement in reaching any conclusion or making any investment decision about any securities of Tempest Therapeutics.
TEMPEST THERAPEUTICS, INC. | |||||||
Consolidated Balance Sheets | |||||||
(in thousands) | |||||||
June 30, 2022 | December 31, 2021 | ||||||
Assets | |||||||
Current assets | |||||||
Cash and cash equivalents | $ | 51,621 | $ | 51,829 | |||
Insurance recovery of legal settlement | 15,000 | 15,000 | |||||
Prepaid expenses and other current assets | 1,686 | 2,134 | |||||
Total current assets | 68,307 | 68,963 | |||||
Property and equipment, net | 1,011 | 1,113 | |||||
Operating lease right-of-use assets | 1,553 | 3,051 | |||||
Other noncurrent assets | 480 | 111 | |||||
Total assets | $ | 71,351 | $ | 73,238 | |||
Liabilities and Stockholders' Equity | |||||||
Current liabilities | |||||||
Accounts payable | $ | 1,448 | $ | 991 | |||
Accrued legal settlement | 15,000 | 15,000 | |||||
Current loan payable | 2,000 | - | |||||
Accrued expenses and other | 2,824 | 2,501 | |||||
Current operating lease liabilities | 1,050 | 1,442 | |||||
Interest payable | 101 | 92 | |||||
Total current liabilities | 22,423 | 20,026 | |||||
Loan payable, net | 13,301 | 15,069 | |||||
Operating lease liabilities | 695 | 2,026 | |||||
Total liabilities | 36,419 | 37,121 | |||||
Stockholders' equity | |||||||
Common stock | 10 | 7 | |||||
Additional paid-in capital | 152,644 | 136,173 | |||||
Accumulated deficit | (117,722 | ) | (100,063 | ) | |||
Total stockholders' equity | 34,932 | 36,117 | |||||
Total liabilities and stockholders' equity | $ | 71,351 | $ | 73,238 | |||
TEMPEST THERAPEUTICS, INC. | |||||||||||||||
Consolidated Statements of Operations | |||||||||||||||
(in thousands except per share amounts) | |||||||||||||||
Three months ended | Three months ended | Six months ended | Six months ended | ||||||||||||
June 30, 2022 | June 30, 2021 | June 30, 2022 | June 30, 2021 | ||||||||||||
Expenses: | |||||||||||||||
Research and development | $ | 5,651 | $ | 4,229 | $ | 10,760 | $ | 7,821 | |||||||
General and administrative | 3,123 | 2,556 | 6,175 | 4,091 | |||||||||||
Total expenses | 8,774 | 6,785 | 16,935 | 11,912 | |||||||||||
Operating loss | (8,774 | ) | (6,785 | ) | (16,935 | ) | (11,912 | ) | |||||||
Other income (expense), net: | |||||||||||||||
Interest expense | (464 | ) | (276 | ) | (797 | ) | (507 | ) | |||||||
Interest and other income, net | 70 | 3 | 73 | 6 | |||||||||||
Net loss | $ | (9,168 | ) | $ | (7,058 | ) | $ | (17,659 | ) | $ | (12,413 | ) | |||
Net loss per share | $ | (0.79 | ) | $ | (7.63 | ) | $ | (1.88 | ) | $ | (17.30 | ) | |||
Investor Contacts:Sylvia WheelerWheelhouse Life Science Advisorsswheeler@wheelhouselsa.com
Aljanae Reynolds Wheelhouse Life Science Advisorsareynolds@wheelhouselsa.com
1 If approved by the FDA
1 Year Tempest Therpeutics Chart |
1 Month Tempest Therpeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions